AGAM
PBYI icon

Avalon Global Asset Management’s Puma Biotechnology PBYI Stock Holding History

Avalon Global Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-7,500
Closed -$495K – 61
2014
Q2 		$495K Buy
+7,500
New +$533K 0.3% 54

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avalon Global Asset Management's PBYI Position: Q4 2015 in Review

Avalon Global Asset Management sold out of Puma Biotechnology (PBYI) in Q4 2015, closing a stake of 32,900 shares — an estimated $2.48M sold.

Avalon Global Asset Management first reported a position in PBYI in Q2 2014 and held it in 6 quarters. The position peaked at $3.82M in Q3 2014. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2015.

  • Avalon Global Asset Management reported no remaining Puma Biotechnology position as of Q4 2015 after selling out during the quarter.
  • Avalon Global Asset Management sold 32,900 Puma Biotechnology shares in Q4 2015, an estimated $2.48M.
  • Avalon Global Asset Management first reported a position in Puma Biotechnology in Q2 2014 and held it in 6 quarters.
  • Avalon Global Asset Management's Puma Biotechnology position peaked at $3.82M in Q3 2014.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2015.

Based on Avalon Global Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.